Synthesis and immunogenicity of the arabinomannan-CRM197 conjugate
Lipoarabinomannan (LAM) is a major structural surface component of Mycobacterium tuberculosis . This study describes the synthesis of the well-defined lipoarabinomannan (LAM) specific dodecasaccharide-protein conjugate and immunological studies. Arabinomannan (AM) dodecasaccharide has been efficient...
Gespeichert in:
| Veröffentlicht in: | MedChemComm 2019-04, Vol.1 (4), p.543-553 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 553 |
|---|---|
| container_issue | 4 |
| container_start_page | 543 |
| container_title | MedChemComm |
| container_volume | 1 |
| creator | Chang, Yunsong Meng, Xin Li, Yaxin Liang, Jianmei Li, Tingshen Meng, Demei Zhu, Tao Yu, Peng |
| description | Lipoarabinomannan (LAM) is a major structural surface component of
Mycobacterium tuberculosis
. This study describes the synthesis of the well-defined lipoarabinomannan (LAM) specific dodecasaccharide-protein conjugate and immunological studies. Arabinomannan (AM) dodecasaccharide has been efficiently synthesized and covalently conjugated to carrier proteins, including cross reactive mutant (CRM197) diphtheria toxoid and bovine serum albumin (BSA) for novel neoglycoconjugates, creating a potent T-dependent conjugate vaccine. Preliminary mice immunization studies on the neoglycoconjugate revealed that it could give rise to a strong IgG antibody titer in mice at 4.0 μg dose with an aluminum phosphate adjuvant. AM-CRM197 shows potential as an excellent candidate for a new carbohydrate-based vaccine that would be capable of eliciting a protective immune response against tuberculosis.
This paper describes the synthesis of the well-defined lipoarabinomannan (LAM) specific dodecasaccharide-protein conjugate and immunological studies. |
| doi_str_mv | 10.1039/c8md00546j |
| format | Article |
| fullrecord | <record><control><sourceid>rsc</sourceid><recordid>TN_cdi_rsc_primary_c8md00546j</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>c8md00546j</sourcerecordid><originalsourceid>FETCH-rsc_primary_c8md00546j3</originalsourceid><addsrcrecordid>eNqFjrEOgjAURRujiURZ3E36A-grBYVVonFxUXdSS8ES-2paGPh7HYyO3uWc5CyXkAWDFQOer2VmKoA02bQjEsSQQBSnjI2_DnxKQu9beI_HWZYnAdldBuzuymtPBVZUG9OjbRRqqbuB2pq-IxVO3DRaIxAFRsX5xPItlRbbvhGdmpNJLR5ehR_OyPKwvxbHyHlZPp02wg3l7xv_11-3rzwa</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Synthesis and immunogenicity of the arabinomannan-CRM197 conjugate</title><source>Royal Society Of Chemistry Journals 2008-</source><source>PubMed Central</source><creator>Chang, Yunsong ; Meng, Xin ; Li, Yaxin ; Liang, Jianmei ; Li, Tingshen ; Meng, Demei ; Zhu, Tao ; Yu, Peng</creator><creatorcontrib>Chang, Yunsong ; Meng, Xin ; Li, Yaxin ; Liang, Jianmei ; Li, Tingshen ; Meng, Demei ; Zhu, Tao ; Yu, Peng</creatorcontrib><description>Lipoarabinomannan (LAM) is a major structural surface component of
Mycobacterium tuberculosis
. This study describes the synthesis of the well-defined lipoarabinomannan (LAM) specific dodecasaccharide-protein conjugate and immunological studies. Arabinomannan (AM) dodecasaccharide has been efficiently synthesized and covalently conjugated to carrier proteins, including cross reactive mutant (CRM197) diphtheria toxoid and bovine serum albumin (BSA) for novel neoglycoconjugates, creating a potent T-dependent conjugate vaccine. Preliminary mice immunization studies on the neoglycoconjugate revealed that it could give rise to a strong IgG antibody titer in mice at 4.0 μg dose with an aluminum phosphate adjuvant. AM-CRM197 shows potential as an excellent candidate for a new carbohydrate-based vaccine that would be capable of eliciting a protective immune response against tuberculosis.
This paper describes the synthesis of the well-defined lipoarabinomannan (LAM) specific dodecasaccharide-protein conjugate and immunological studies.</description><identifier>ISSN: 2040-2503</identifier><identifier>EISSN: 2040-2511</identifier><identifier>DOI: 10.1039/c8md00546j</identifier><ispartof>MedChemComm, 2019-04, Vol.1 (4), p.543-553</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Chang, Yunsong</creatorcontrib><creatorcontrib>Meng, Xin</creatorcontrib><creatorcontrib>Li, Yaxin</creatorcontrib><creatorcontrib>Liang, Jianmei</creatorcontrib><creatorcontrib>Li, Tingshen</creatorcontrib><creatorcontrib>Meng, Demei</creatorcontrib><creatorcontrib>Zhu, Tao</creatorcontrib><creatorcontrib>Yu, Peng</creatorcontrib><title>Synthesis and immunogenicity of the arabinomannan-CRM197 conjugate</title><title>MedChemComm</title><description>Lipoarabinomannan (LAM) is a major structural surface component of
Mycobacterium tuberculosis
. This study describes the synthesis of the well-defined lipoarabinomannan (LAM) specific dodecasaccharide-protein conjugate and immunological studies. Arabinomannan (AM) dodecasaccharide has been efficiently synthesized and covalently conjugated to carrier proteins, including cross reactive mutant (CRM197) diphtheria toxoid and bovine serum albumin (BSA) for novel neoglycoconjugates, creating a potent T-dependent conjugate vaccine. Preliminary mice immunization studies on the neoglycoconjugate revealed that it could give rise to a strong IgG antibody titer in mice at 4.0 μg dose with an aluminum phosphate adjuvant. AM-CRM197 shows potential as an excellent candidate for a new carbohydrate-based vaccine that would be capable of eliciting a protective immune response against tuberculosis.
This paper describes the synthesis of the well-defined lipoarabinomannan (LAM) specific dodecasaccharide-protein conjugate and immunological studies.</description><issn>2040-2503</issn><issn>2040-2511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqFjrEOgjAURRujiURZ3E36A-grBYVVonFxUXdSS8ES-2paGPh7HYyO3uWc5CyXkAWDFQOer2VmKoA02bQjEsSQQBSnjI2_DnxKQu9beI_HWZYnAdldBuzuymtPBVZUG9OjbRRqqbuB2pq-IxVO3DRaIxAFRsX5xPItlRbbvhGdmpNJLR5ehR_OyPKwvxbHyHlZPp02wg3l7xv_11-3rzwa</recordid><startdate>20190417</startdate><enddate>20190417</enddate><creator>Chang, Yunsong</creator><creator>Meng, Xin</creator><creator>Li, Yaxin</creator><creator>Liang, Jianmei</creator><creator>Li, Tingshen</creator><creator>Meng, Demei</creator><creator>Zhu, Tao</creator><creator>Yu, Peng</creator><scope/></search><sort><creationdate>20190417</creationdate><title>Synthesis and immunogenicity of the arabinomannan-CRM197 conjugate</title><author>Chang, Yunsong ; Meng, Xin ; Li, Yaxin ; Liang, Jianmei ; Li, Tingshen ; Meng, Demei ; Zhu, Tao ; Yu, Peng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-rsc_primary_c8md00546j3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, Yunsong</creatorcontrib><creatorcontrib>Meng, Xin</creatorcontrib><creatorcontrib>Li, Yaxin</creatorcontrib><creatorcontrib>Liang, Jianmei</creatorcontrib><creatorcontrib>Li, Tingshen</creatorcontrib><creatorcontrib>Meng, Demei</creatorcontrib><creatorcontrib>Zhu, Tao</creatorcontrib><creatorcontrib>Yu, Peng</creatorcontrib><jtitle>MedChemComm</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, Yunsong</au><au>Meng, Xin</au><au>Li, Yaxin</au><au>Liang, Jianmei</au><au>Li, Tingshen</au><au>Meng, Demei</au><au>Zhu, Tao</au><au>Yu, Peng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and immunogenicity of the arabinomannan-CRM197 conjugate</atitle><jtitle>MedChemComm</jtitle><date>2019-04-17</date><risdate>2019</risdate><volume>1</volume><issue>4</issue><spage>543</spage><epage>553</epage><pages>543-553</pages><issn>2040-2503</issn><eissn>2040-2511</eissn><abstract>Lipoarabinomannan (LAM) is a major structural surface component of
Mycobacterium tuberculosis
. This study describes the synthesis of the well-defined lipoarabinomannan (LAM) specific dodecasaccharide-protein conjugate and immunological studies. Arabinomannan (AM) dodecasaccharide has been efficiently synthesized and covalently conjugated to carrier proteins, including cross reactive mutant (CRM197) diphtheria toxoid and bovine serum albumin (BSA) for novel neoglycoconjugates, creating a potent T-dependent conjugate vaccine. Preliminary mice immunization studies on the neoglycoconjugate revealed that it could give rise to a strong IgG antibody titer in mice at 4.0 μg dose with an aluminum phosphate adjuvant. AM-CRM197 shows potential as an excellent candidate for a new carbohydrate-based vaccine that would be capable of eliciting a protective immune response against tuberculosis.
This paper describes the synthesis of the well-defined lipoarabinomannan (LAM) specific dodecasaccharide-protein conjugate and immunological studies.</abstract><doi>10.1039/c8md00546j</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2040-2503 |
| ispartof | MedChemComm, 2019-04, Vol.1 (4), p.543-553 |
| issn | 2040-2503 2040-2511 |
| language | |
| recordid | cdi_rsc_primary_c8md00546j |
| source | Royal Society Of Chemistry Journals 2008-; PubMed Central |
| title | Synthesis and immunogenicity of the arabinomannan-CRM197 conjugate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T23%3A16%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-rsc&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20immunogenicity%20of%20the%20arabinomannan-CRM197%20conjugate&rft.jtitle=MedChemComm&rft.au=Chang,%20Yunsong&rft.date=2019-04-17&rft.volume=1&rft.issue=4&rft.spage=543&rft.epage=553&rft.pages=543-553&rft.issn=2040-2503&rft.eissn=2040-2511&rft_id=info:doi/10.1039/c8md00546j&rft_dat=%3Crsc%3Ec8md00546j%3C/rsc%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |